The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Windows to the BrainFull Access

Metachromatic Leukodystrophy: A Model for the Study of Psychosis

Published Online:

Metachromatic leukodystrophy (MLD) is a demyelinating genetic disorder in which neuropsychiatric abnormalities, including psychotic features similar to those present in schizophrenia, are prominent symptoms. Although rare, it is a valuable model for the study of psychosis.2 MLD occurs worldwide with an estimated frequency of 1/40,000, although several clusters of much higher frequency have been identified.3 MLD is caused by an autosomal recessive mutation on chromosome 22q, resulting in the near-complete absence of the lysosomal enzyme arylsulfatase A (ARS-A). More than 57 mutations of the ARS-A gene have been identified, including 31 amino acid substitutions, 1 nonsense mutation, 3 deletions, 3 splice donor site mutations, and 1 combined missense-splice donor site mutation.3,4 There is also an ARS-A pseudodeficiency, with a frequency of around 16% in the general population.5 These patients, who appear clinically healthy, are thought to be compound heterozygotes for the deficient allele and another allele coding for low enzyme activity. MLD can be mimicked by genetically unrelated deficiency of cerebroside sulfatase activator and multiple sulfatase deficiency.

Metachromatic material (cerebroside sulfate) accumulates in brain oligodendrocytes and microglia, peripheral nerve Schwann cells, kidneys; and it is excreted in urine. The accumulation of this material leads to abnormal myelin formation and myelin degeneration by unknown pathophysiological mechanisms. Diagnosis of MLD may be suspected when metachromatic granules are found in conjunctival or sural nerve biopsy.6 Definitive diagnosis relies on the confirmation of low ARS-A activity in leukocytes or cultured fibroblasts.3 The clinical phenotype of MLD is divided into late infantile, juvenile, and adult-onset forms. The late infantile form, which is the most common, presents before age 2, with weakness, muscular hypotonia and delayed motor and intellectual milestones. Death usually occurs before age 5 in a rigid, vegetative state. Juvenile MLD most commonly presents between 4 and 10 years of age. The distinction between juvenile and adult-onset MLD is arbitrarily set at age 16.

Both the juvenile and adult-onset forms are distinguished from late infantile MLD by slower progression, higher residual ARS-A activity, and a preponderance of neuropsychiatric abnormalities, including conduct disorder, nonverbal learning disability, alcohol or substance abuse, depression, and schizophrenia-like psychosis.3,7,8 Baumann et al.7 described two distinct clinical patterns of adult MLD.7 One presents with predominantly motor manifestations similar to those found in infantile cases. The other presents as a schizophrenia-like psychosis, with prominent negative signs (e.g., psychomotor slowing, apathy, apragmatism, poor judgment, and disorganized thinking). The cognitive profile resembles a subcortical dementia, including impaired verbal fluency, impaired memory retrieval, and executive dysfunction. Disinhibition, anosognosia, complex delusions, bizarre behavior, and auditory hallucinations may also occur.7,9 Extrapyramidal symptoms, including choreoathetosis and dystonia, seizures, and peripheral neuropathy rarely occur. Some variability is probably related to different mutations within the ARS-A gene. For example, adult MLD patients with primarily psychiatric manifestations may carry mutations in regions of the ARS-A gene that are distinct from the common P426L mutation found in most patients with motor signs.7 However, strict genotype-phenotype correlations do not apply in all cases, and genetic background probably modifies the clinical profile.4 Whatever the age of onset, progression is the rule. Motor signs can be absent until decades into the illness despite the characteristic white matter appearance on neuroimaging.10 The prominent behavioral disturbance and more subtle initial cognitive dysfunction combined with the lack of motor signs can make recognition of this degenerative dementia challenging. All cases eventually manifest dementia and spasticity.

It is unclear at this time whether the neuropsychiatric profile of adult MLD is a direct manifestation of low ARS-A activity or whether neuropsychiatric abnormalities, particularly psychosis, reflect disruption of brain white matter tracts. In favor of the low-ARS-A-activity-neuropsychiatric-phenotype model is the observation of increased psychopathology in some first-degree relatives of MLD patients. These individuals are presumably heterozygote carriers of one defective allele of the ARS-A gene.8 Subtle deficits in visuospatial perception, construction, stereognosis, and visual search tasks have been found in MLD heterozygotes.11

STRUCTURAL IMAGING

Computed tomography (CT) findings in MLD consist of confluent attenuation of signal from hemispheric white matter (Figure 1). This is particularly marked in frontal and parietal regions. Later signs include progressive cortical and subcortical atrophy and ventricular dilatation ex vacuo.9,12 White matter hypodensities on CT probably reflect myelin loss rather than pathological accumulation of cerebroside.12

Magnetic resonance imaging (MRI) is more sensitive than CT for the detection of white matter lesions of the brain (Figure 2).13 MRI is particularly useful for the visualization of early lesions, involvement of posterior fossa structures (brainstem and cerebellum) and for evaluating the severity and extent of the disease.14 On T1 (inversion recovery)-weighted sequences, brain white matter has high signal, which reflects the presence of free water in the 150 nm spaces between the myelin lamellae. In contrast, brain white matter has low signal and cerebrospinal fluid (CSF) is hyperintense on T2-weighted sequences, which are more useful than T1 sequences for the detection of lesions of myelin.13 FLAIR (fluid-attenuated inversion recovery) sequences produce T2 weighted images with the additional advantage of suppressing the CSF signal, facilitating the distinction between white matter lesions and enlarged Virchow-Robin spaces and lacunes.13

Like other leukodystrophies, MLD is distinguished from the asymmetrical white matter changes of normal aging, small-vessel disease, and multiple sclerosis by relatively symmetrical and confluent involvement of the hemispheric white matter. Most cases show lack of enhancement after contrast agent administration, although Kim et al.15 reported linear enhancement of radial bands of intact perivascular myelin alternating with affected myelin in a tigroid or spotty pattern in 6 affected children, a pattern similar to Pelizaeus-Merzbacher leukodystrophy.15 Progressive demyelination is believed to spread anteriorly to posteriorly, although exceptions to this pattern may occur.15 Subcortical U-fibers are initially spared.15 MLD has the added distinction of early and extensive involvement of the corpus callosum, internal capsules, corticospinal tracts in the brainstem, and deep cerebellar white matter.13,15 Abnormal low signal in the thalami on T2-weighted images has also been reported.14,15 Despite these features, T2 weighted MRI alone cannot definitively distinguish MLD from other dysmyelinating leukodystrophies, such as adrenoleukodystrophy and Krabbe's (globoid cell) leukodystrophy.14

Diffusion weighted MR (DWI), which is sensitive to the mobility of water in tissue, may be more specific than standard T2-weighted MRI in distinguishing MLD from other leukodystrophies, although there are few studies at present.16,17 The apparent diffusion constant (ADC) was reduced in the deep white matter (indicating more restricted diffusion) of an infant with MLD on images acquired at 10 and 16 months of age. Restriction of diffusion in the diseased white matter was similar to the changes seen in cytotoxic edema.17 Reduced ADC within the corpus callosum and inner portions of the centrum semiovale was also found in a 4½ year-old child with MLD.16 The authors suggest that the accumulation of lysosomal membrane-bound sulfatides may restrict the movement of water in affected tissue.16 In addition, directionality of diffusion, which is normally high in white matter, was also very low. The authors suggest that this may result from the extremely restricted diffusion in the affected white matter. These results are in contrast to most other leukodystrophies examined in this study, in which the ADC was increased, indicating less restricted diffusion.

In late-onset MLD, where the clinical presentation may resemble a primary psychiatric disorder, MRI is particularly useful in indicating the presence of white matter disease; indeed, pathological involvement of white matter may be seen on MRI before the onset of typical clinical signs.12 MRI may, therefore, be a useful adjunct to biochemical screening for early disease detection in affected families.14 Serial MRI may be a useful adjunct to clinical neurobehavioral evaluation to document decrease or stabilization of white matter pathology following therapeutic bone marrow transplantation.18

FUNCTIONAL IMAGING

Salmon et al.9 obtained positron emission tomography (PET) in a woman with enzymatically confirmed MLD who presented with cognitive changes in her mid-30s.9 In contrast to the subcortical involvement of white matter on CT and MRI, hypometabolism was observed bilaterally in the thalamus, medial frontal cortex, frontal poles, and occipital cortex. This pattern differed from the characteristic dorsolateral prefrontal, parietal and posterior temporal association cortical hypometabolism in Alzheimer's dementia (AD). Tamagaki et al.19 reported similar lack of correlation between T2 weighted MRI subcortical abnormalities and cortical hypoperfusion on SPECT in a patient with adult-onset MLD who presented behavioral abnormalities, euphoria, personality changes, and dementia.19 Widespread functionally interconnected cortical regions may be disconnected by subcortical lesions. The clinical repercussions may resemble a primary cortical lesion (diaschisis) (Figure 3).

A MODEL OF PSYCHOSIS

Late-onset MLD has been proposed as a naturally occurring model of schizophrenia.2,20 The psychotic and cognitive features of late-onset MLD are extremely similar to those of schizophrenia. Both disorders are characterized by widespread anatomic dysconnectivity and secondary functional disruption. The prominent executive dysfunction in both MLD and schizophrenia reflects extensive disruption of frontal-subcortical circuits, which subserve mood, motivation, behavioral regulation, planning, and judgment.21 Although abundant evidence suggests that schizophrenia is predominantly a disease of gray matter and MLD is a disease of white matter, there is evidence of neuronal dysfunction in MLD and white matter abnormalities in schizophrenia.2224 Decreased fractional anisotropy in the inferior frontal white matter is inversely correlated with negative symptoms in schizophrenia.25 Furthermore, the anatomical distinction between cortical and subcortical disease is not corroborated by either clinical observation or functional imaging. A functional disturbance of neuronal metabolism and activity at a remote site after injury to an anatomically connected area of brain (diaschisis) is frequently found, and it may be the explanation for the SPECT observation of thalamic and widespread cortical hypoperfusion in the adult case of MLD, above.9,19

Some refractory patients with schizophrenia have been shown to have ARS-A pseudodeficiency or intermediate ARS-A levels between normal and deficient.8 This supports the suggestion that accumulation of cerebroside sulfate is toxic to the brain. However, these observations have not been consistently replicated, in part because of differing assay techniques, widely variable normal ARS-A levels, and poorly controlled case definition. Additionally, it has not been definitively established that ARS-A deficiency or pseudodeficiency is higher in the psychiatric population than in the general population.5,8,26,27 One interpretation of these discrepant results, based on in vitro studies, is that low-enzyme activity individuals may be at greater risk of neuropsychiatric disability if they are exposed to environmental or endogenous stressors such as ethanol consumption.8,11 An additional interpretation of these discrepant findings is that there may be a subgroup of patients with schizophrenia who have low ARS-A levels. These could be obscured by mean group comparisons.28

Evidence for the importance of white matter pathology in both schizophrenia and MLD is compelling. It has been proposed that schizophrenia is characterized by a developmentally mediated abnormal connectivity (“dysconnectivity”) between the prefrontal and mesiotemporal cortex.29,30 In this model, subtle disorganization of cortical cytoarchitecture leads to disruption of neuronal circuits in widely distributed, functionally interrelated brain regions.31 Loss of the normally dense and reciprocal projections between the prefrontal and limbic cortex is supported by anatomical studies showing reversal of the normal positive correlation between the volumes of left prefrontal cortex, superior temporal cortex, and hippocampus in patients with schizophrenia.32 Functional imaging studies suggest that hypoactivation of prefrontal cortex is associated with dysregulation of mesiotemporal and ventral striatal regions, overactivity of limbic dopaminergic systems, and the “positive” manifestations of psychosis, namely, hallucinations and delusions.33,34 Secondary disruption of white matter tracts is suggested by the finding of reduced volume of the mid-corpus callosum, which conveys axonal projections between the temporal lobes.35 Some diffusion tensor imaging studies in schizophrenics show lower diffusion anisotropy in the prefrontal white matter and in the splenium of the corpus callosum relative to healthy controls (but cf).3639 Disruption of white matter may be secondary to cortical neuronal dysfunctio, or a primary deficit in myelin gene expression in oligodendroglia.13,40,41

CONCLUSION

There are several parallels between MLD and schizophrenia that support the value of MLD as a model for psychosis. To date, it is not clear whether MLD resembles schizophrenia because of widespread cortical and subcortical disconnection in both diseases or whether specific brain sites must be involved to cause the clinical phenotype of schizophrenia, independent of pathology. What is needed are comparisons of the areas of anatomical overlap between MLD and schizophrenia to define the necessary common ground for clinical disease. Suzuki et al., using three-dimensional MRI in a group of patients with schizophrenia, reported significant white matter decrease in the anterior limbs of the internal capsules and superior occipitofrontal fasciculus.42 In contrast, Kim et al.15 described white matter changes in the posterior limb of the internal capsule in a group of seven children with infantile MLD.15 The anterior limbs were spared in all cases. The anterior limb of the internal capsule conveys reciprocal connections between the dorsomedian thalamus and the prefrontal cortex, while the posterior limb of the internal capsule conveys mostly corticospinal and corticobulbar motor fibers. The schizophreniform psychosis in adult MLD may reflect involvement of the thalamus in this condition, with secondary repercussions in the prefrontal cortex.9 Further careful anatomical and functional neuroimaging studies will be useful in defining the anatomical substrate for diverse neuropsychiatric disorders with overlapping clinical manifestations.

COVER A three dimensional reconstruction of the white matter lesions (orange) and ventricles (yellow) of a young child with metachromatic leukodystrophy. It is surrounded by the two-dimensional axial magnetic resonance images from which it was created. (Reprinted with permission from Minamikawa-Tachino et al.1

FIGURE 1.

FIGURE 1.  Serial CT in a young adult female patient with adult-onset metachromatic leukodystrophy (MLD). Axial CT images (left) of a female with auditory hallucinations, agitation, grandiose and paranoid delusions. Cognitive testing showed IQ 78, attentional errors, psychomotor slowing, impaired verbal and nonverbal memory, and concreteness. Behavioral changes began at age 17 with deterioration of school performance, promiscuity, and polysubstance abuse. Note the enlarged ventricles and white matter attenuation. Follow-up CT (right) 9 years later showed progression of white matter attenuation and increased ventricular size, consistent with cerebral atrophy. Concurrently she exhibited urinary and fecal incontinence, global deficiencies in self-care, marked apathy, and was unable to name the month or recite the alphabet. Pseudobulbar affect, imitation behavior, primitive and brisk tendon reflexes without other neurological abnormalities were present. Arylsulfatase A was absent in leukocytes. An older brother was similarly but more severely affected

FIGURE 2.

FIGURE 2.  Serial MRI in a middle-aged male patient with adult-onset metachromatic leukodystrophy (MLD). Axial MR images (left) of a male who developed difficulty with walking and coordination. After a full neurological work-up and brain biopsy, the patient was determined to have adult-onset MLD. Note the ventricular enlargement and hyperintense signal around the ventricles on T2 and SD images, indicating white matter disease. Two years later, the patient developed psychiatric symptoms, including disinhibition, aggression, and depression. Followup MR images 4 years after onset (right) showed greatly enlarged ventricles and significant atrophy, consistent with the worsening of the patient's symptoms, including gait instability and bowel/bladder incontinence.

FIGURE 3.

FIGURE 3.  Companion SPECT images. Single photon emission computed tomography (SPECT) acquired at the same time as the second set of MR images (Figure 2. , right) showed ventricular enlargement, significant atrophy, and decreased perfusion, especially in frontal lobe gray and white matter (arrows).

From the Department of Neurology, University of Vermont, Burlington, Vermont (d.n.b.); Departments of Radiology and of Psychiatry and Behavioral Sciences and the Herbert J. Frensley Center for Imaging Research, Baylor College of Medicine, Houston, Texas (k.h.t., r.a.h.); and the Psychiatry Service, Houston Veterans Affairs Medical Center, Houston, Texas (r.a.h.). Address correspondence to Dr. Taber, University of Texas-Houston, School of Health Information Sciences, 7000 Fannin, UCT 880, Houston, TX 77030; (E-mail).
References

1 Minamikawa-Tachino R, Maeda Y et al: Three-dimensional brain visualization for metachromatic leukodystrophy. Brain Dev 1996; 18:394–399Crossref, MedlineGoogle Scholar

2 Hyde TM, Ziegler JC, Weinberger DR: Psychiatric disturbances in metachromatic leukodystropy. Insights into the neurobiology of psychosis. Arch Neurol 1992; 49:401–406Crossref, MedlineGoogle Scholar

3 McKusick VA: Metachromatic leukodystrophy. Online Mendelian Inheritance in Man, 2003Google Scholar

4 Berger J, Loschl B, et al: Occurrence, distribution, and phenotype of arylsulfatase a mutations in patients with metachromatic leukodystrophy. Am J Med Genet 1997; 69:335–340Crossref, MedlineGoogle Scholar

5 Propping P, Friedl W, et al: The influence of low arylsulfatase-a activity on neuropsychiatric morbidity—a large-scale screening in patients. Human Genetics 1986; 74:244–248Crossref, MedlineGoogle Scholar

6 Blackwood W, Corsellis JAN: Greenfield's Neuropathology, 1976Google Scholar

7 Baumann N, Turpin JC, et al: Motor and psycho-cognitive clinical types in adult metachromatic leukodystrophy: genotype/phenotype relationships? J Physiology—Paris 2002; 96:301–306Crossref, MedlineGoogle Scholar

8 Fluharty AL: The relationship of the metachromatic leukodystrophies to neuropsychiatric disorders. Molecular and Chemical Neuropathology 1990; 13:81–94Crossref, MedlineGoogle Scholar

9 Salmon E, Van der Linden M, et al: Early thalamic and cortical hypometabolism in adult-onset dementia due to metachromatic leukodystrophy. Acta Neurologica Belgica 1999; 99:185–188MedlineGoogle Scholar

10 Finelli PF: Metachromatic leukodystrophy manifesting as a schizophrenic disorder—computed tomographic correlation. Annals of Neurology 1985; 18:94–95Crossref, MedlineGoogle Scholar

11 Kohn H, Manowitz P, et al: Neuropsychological deficits in obligatory heterozygotes for metachromatic leukodystrophy. Human Genetics 1988; 79:8–12Crossref, MedlineGoogle Scholar

12 Reider-Grosswasser I, Bornstein N: CT and MRI in late-onset metachromatic leukodystrophy. Acta Neurol Scand 1987; 75:64–69Crossref, MedlineGoogle Scholar

13 Barkhof F, Scheltens P: Imaging of white matter lesions. Cerebrovascular Diseases 2002; 13:21–30Crossref, MedlineGoogle Scholar

14 Demaerel P, Faubert C, et al: MR findings in leukodystrophy. Neuroradiology 1991; 33:368–371Crossref, MedlineGoogle Scholar

15 Kim TS, Kim IO, et al: MR of childhood metachromatic leukodystrophy. Am J Neuroradiology 1997; 18:733–738MedlineGoogle Scholar

16 Engelbrecht V, Scherer A, et al: Diffusion-weighted MR imaging in the brain in children: findings in the normal brain and in the brain with white matter diseases. Radiology 2002; 222:410–418Crossref, MedlineGoogle Scholar

17 Sener RN: Metachromatic leukodystrophy: diffusion MR imaging findings. Am J Neuroradiology 2002; 23:1424–1426MedlineGoogle Scholar

18 Stillman AE, Krivit W, et al: Serial MR after bone-marrow transplantation in 2 patients with metachromatic leukodystrophy. Am J Neuroradiology 1994; 15:1929–1932MedlineGoogle Scholar

19 Tamagaki C, Murata A, et al: Two siblings with adult-type metachromatic leukodystrophy: correlation between. Seishin Shinkeigaku Zasshi 2000; 102:399–409MedlineGoogle Scholar

20 Holden C: Neuroscience: deconstructing schizophrenia. Science 2003; 299:333–335Crossref, MedlineGoogle Scholar

21 Lim KO, Helpern JA: Neuropsychiatric applications of DTI—a review. NMR in Biomedicine 2002; 15:587–593Crossref, MedlineGoogle Scholar

22 Mega MS, Cummings JL: Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci 1994; 6:358–370LinkGoogle Scholar

23 Alves D, Pires MM, et al: 4 Cases of late onset metachromatic leukodystrophy in a family—clinical, biochemical and neuropathological studies. J Neurol Neurosurg Psychiatry 1986; 49:1417–1422Crossref, MedlineGoogle Scholar

24 Goebel HH, Argyrakis A, et al: Adult metachromatic leukodystrophy, 4: ultrastructural studies on the central and peripheral nervous-system. European Neurology 1980; 19:294–307Crossref, MedlineGoogle Scholar

25 Wolkin A, Choi SJ, et al: Inferior frontal white matter anisotrophy and negative symptoms of schizophrenia: a diffusion tensor imaging study. Am J Psychiatry 2003; 160:572–574Crossref, MedlineGoogle Scholar

26 Lejoyeux M, Dubois G, et al: Arylsulfatase A activity among psychotic-patients. Psychiatry Res 1989; 30:107–108Crossref, MedlineGoogle Scholar

27 Shah SN: Arylsulfatase A (Asa) defect and psychiatric-illness—a review. Molecular and Chemical Neuropathology 1990; 12:121–129Crossref, MedlineGoogle Scholar

28 Heavey AM, Philpot MP, et al: Leukocyte arylsulfatase-A activity and subtypes of chronic schizophrenia. Acta Psychiatrica Scandinavica 1990; 82:55–59Crossref, MedlineGoogle Scholar

29 Meyer-Lindenberg A, Poline JB, et al: Evidence for abnormal cortical functional connectivity during working memory in schizophrenia. Am J Psychiatry 2001; 158:1809–1817Crossref, MedlineGoogle Scholar

30 Bullmore ET, Frangou S, Murray RM: The dysplastic net hypothesis: an integration of developmental and dysconnectivity theories of schizophrenia. Schizophrenia Res 1997; 28:143–156Crossref, MedlineGoogle Scholar

31 Weinberger DR, Lipska BK: Cortical maldevelopment, antipsychotic-drugs, and schizophrenia—a search for common ground. Schizophrenia Res 1995; 16:87–110Crossref, MedlineGoogle Scholar

32 Woodruff PW, Wright IC, et al: Structural brain abnormalities in male schizophrenics reflect fronto-temporal dissociation. Psychol Med 1997; 27:1257–1266Crossref, MedlineGoogle Scholar

33 Epstein J, Stern E, Silbersweig D: Mesolimbic activity associated with psychosis in schizophrenia—symptom-specific PET studies. Advancing from the Ventral Striatum to the Extended Amygdala 1999; 877:562–574Google Scholar

34 Silbersweig DA, Stern E, et al: A functional neuroanatomy of hallucinations in schizophrenia. Nature 1995; 378:176–179Crossref, MedlineGoogle Scholar

35 Woodruff PW, Pearlson GD, et al: A computerized magnetic resonance imaging study of corpus callosum morphology in schizophrenia. Psychol Med 1993; 23:45–56Crossref, MedlineGoogle Scholar

36 Foong J, Maier M, et al: Neuropathological abnormalities of the corpus callosum in schizophrenia: a diffusion tensor imaging study. J Neurol Neurosurg Psychiatry 2000; 68:242–244Crossref, MedlineGoogle Scholar

37 Buchsbaum MS, Tang CY, et al: MRI white matter diffusion anisotropy and PET metabolic rate in schizophrenia. Neuroreport 1998; 9:425–430Crossref, MedlineGoogle Scholar

38 Agartz I, Andersson JLR, Skare S: Abnormal brain white matter in schizophrenia: a diffusion tensor imaging study. Neuroreport 2001; 12:2251–2254Crossref, MedlineGoogle Scholar

39 Foong J, Symms MR, et al: Investigating regional white matter in schizophrenia using diffusion tensor imaging. Neuroreport 2002; 13:333–336Crossref, MedlineGoogle Scholar

40 Steel RM, Bastin ME, et al: Diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy (H-1 MRS) in schizophrenic subjects and normal controls. Psychiatry Research-Neuroimaging 5–30–2001; 106:161–170Google Scholar

41 Holden C: Neuroscience. White matter's the matter. Science 2003; 299:334–334Crossref, MedlineGoogle Scholar

42 Suzuki M, Nohara S, et al: Regional changes in brain gray and white matter in patients with schizophrenia demonstrated with voxel-based analysis of MRI. Schizophr Res 2002; 55:41–54Crossref, MedlineGoogle Scholar